Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 530 | 111 | 412 |
| Samples | 495 | 98 | 391 |
| Peptides | 327 | 65 | 278 |
Function
SLC6A19 · Solute carrier family 6 member 19
This gene encodes a system B(0) transmembrane protein that actively transports most neutral amino acids across the apical membrane of epithelial cells. Mutations in this gene may result in Hartnup disorder, an inherited disease with symptoms such as pellagra, cerebellar ataxia, and psychosis. The expression and function of B0AT1 (SLC6A19) in intestinal cells depends on the presence of the accessory protein angiotensin-converting enzyme 2 (ACE2) which, among other functions, acts as a chaperone for membrane trafficking of B0AT1. The ACE2 is also the cellular receptor for severe acute respiratory syndrome-coronavirus (SARS-CoV) and for SARS-CoV-2 that is causing the coronavirus 2019 (COVID-19) pandemic [provided by RefSeq, Jul 2020].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000304460 | Q695T7 | 530 | 327 |
Gene Properties
Recurrent Mutations
All 327 amino-acid changes on canonical ENST00000304460 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SLC6A19 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SLC6A19 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 20/612 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Melanoma | 7/210 3% | 56/1899 3% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 27/1390 2% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 21/810 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Colorectal Carcinoma | 22/143 15% | 49/3239 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Small Cell Lung Carcinoma | 2/9 22% | 11/752 1% |
| Other Solid Cancers | 2/94 2% | 24/1515 2% |
| Cervical Carcinoma | 3/35 9% | 4/422 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Gastric Carcinoma | 2/74 3% | 24/1809 1% |
| Bladder Carcinoma | 0/58 0% | 14/956 1% |
| Neuroendocrine Tumour | 6/154 4% | 4/577 1% |
| Glioma | 2/52 4% | 18/2127 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Biliary Tract Carcinoma | 0/54 0% | 8/950 1% |
| Other Sarcomas | 3/69 4% | 3/699 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 19/2550 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Hepatocellular Carcinoma | 2/46 4% | 14/2210 1% |
| Head and Neck Carcinoma | 0/85 0% | 11/1574 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Prostate Carcinoma | 2/13 15% | 9/2105 0% |
| Kidney Carcinoma | 0/85 0% | 10/1862 1% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Breast Carcinoma | 3/144 2% | 11/3264 0% |
| Ovarian Carcinoma | 3/109 3% | 1/998 0% |
Mutation Distribution
Where SLC6A19 is mutated · all tissues, split by cell line vs tissue
How many mutations in SLC6A19 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 20 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 530 mutations in SLC6A19
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|